What is a Patient Information Leaflet and why is it useful?

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Below is a text only representation of the Patient Information Leaflet. The original can be viewed in PDF format using the link above.

The text only version may be available from RNIB in large print, Braille or audio CD. For further information call RNIB Medicine Leaflet Line on 0800 198 5000. The product code(s) for this leaflet are: EU/1/08/466/001, EU/1/08/466/002.

Bridion 100 mg/ml solution for injection

Package leaflet: Information for the user

Bridion® 100 mg/mL solution for injection

sugammadex

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have further questions, ask your anaesthetist or doctor.
  • If you get any side effects, talk to your anaesthetist or other doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Bridion is and what it is used for
2. What you need to know before Bridion is given
3. How Bridion is given
4. Possible side effects
5. How to store Bridion
6. Contents of the pack and other information

1. What Bridion is and what it is used for

What Bridion is

Bridion contains the active substance sugammadex. Bridion is considered to be a Selective Relaxant Binding Agent since it only works with specific muscle relaxants, rocuronium bromide or vecuronium bromide.

What Bridion is used for

When you have some types of operations, your muscles must be completely relaxed. This makes it easier for the surgeon to do the operation. For this, the general anaesthetic you are given includes medicines to make your muscles relax. These are called muscle relaxants, and examples include rocuronium bromide and vecuronium bromide. Because these medicines also make your breathing muscles relax, you need help to breathe (artificial ventilation) during and after your operation until you can breathe on your own again.

Bridion is used to speed up the recovery of your muscles after an operation to allow you to breathe on your own again earlier. It does this by combining with the rocuronium bromide or vecuronium bromide in your body. It can be used in adults whenever rocuronium bromide or vecuronium bromide is used and in children and adolescents (aged 2 to 17 years) when rocuronium bromide is used for a moderate level of relaxation.

2. What you need to know before Bridion is given

You should not be given Bridion

  • if you are allergic to sugammadex or any of the other ingredients of this medicine (listed in section 6).

  • Tell your anaesthetist if this applies to you.

Warnings and precautions

Talk to your anaesthetist before Bridion is given

  • if you have kidney disease or had in the past. This is important as Bridion is removed from your body by the kidneys.
  • if you have liver disease or have had it in the past.
  • if you have fluid retention (oedema).
  • if you have diseases which are known to give an increased risk of bleeding (disturbances of blood clotting) or anticoagulation medication.

Children and adolescents

This medicine is not recommended for infants less than 2 years of age.

Other medicines and Bridion

  • Tell your anaesthetist if you are taking, have recently taken or might take any other medicines. Bridion may affect other medicines or be affected by them.

Some medicines reduce the effect of Bridion

  • It is especially important that you tell your anaesthetist if you have recently taken:
    • toremifene (used to treat breast cancer).
    • fusidic acid (an antibiotic).

Bridion can affect hormonal contraceptives

  • Bridion can make hormonal contraceptives - including the ‘Pill’, vaginal ring, implants or a hormonal IntraUterine System (IUS) - less effective because it reduces how much you get of the progestogen hormone. The amount of progestogen lost by using Bridion is about the same as missing one oral contraceptive Pill.
    • If you are taking the Pill on the same day as Bridion is given to you, follow the instructions for a missed dose in the Pill’s package leaflet.
    • If you are using other hormonal contraceptives (for example a vaginal ring, implant or IUS) you should use an additional non-hormonal contraceptive method (such as a condom) for the next 7 days and follow the advice in the package leaflet.

Effects on blood tests

In general, Bridion does not have an effect on laboratory tests. However, it may affect the results of a blood test for a hormone called progesterone. Talk to your doctor if your progesterone levels need to be tested on the same day you receive Bridion.

Pregnancy and breast-feeding

  • Tell your anaesthetist if you are pregnant or might be pregnant.

You may still be given Bridion, but you need to discuss it first.

Bridion can be used during breast-feeding.

Driving and using machines

Bridion has no known influence on your ability to drive and use machines.

Bridion contains sodium

Tell your anaesthetist if you are on a controlled salt diet.

3. How Bridion is given

Bridion will be given to you by your anaesthetist, or under the care of your anaesthetist.

The dose

Your anaesthetist will work out the dose of Bridion you need based on:

  • your weight
  • how much the muscle relaxant medicine is still affecting you.

The usual dose is 2-4 mg per kg body weight. A dose of 16 mg/kg can be used in adults if urgent recovery from muscle relaxation is needed.

The dose of Bridion for children is 2 mg/kg (children and adolescents between 2-17 years old).

How Bridion is given

Bridion will be given to you by your anaesthetist. It is given as a single injection through an intravenous line.

If more Bridion is given to you than recommended

As your anaesthetist will be monitoring your condition carefully, it is unlikely that you will be given too much Bridion. But even if this happens, it is unlikely to cause any problems.

If you have any further questions on the use of this medicine, ask your anaesthetist or other doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If these side effects occur while you are under anaesthesia, they will be seen and treated by your anaesthetist.

Common side effects (may affect up to 1 in 10 people)

  • Cough
  • Airway difficulties that may include coughing or moving as if you are waking or taking a breath
  • Light anaesthesia - you may start to come out of deep sleep, so need more anaesthesia. This might cause you to move or cough at the end of the operation
  • Complications during your procedure such as changes in heart rate, coughing or moving
  • Decreased blood pressure due to the surgical procedure

Uncommon side effects (may affect up to 1 in 100 people)

  • Shortness of breath due to muscle cramps of the airways (bronchospasm) occurred in patients with a history of lung problems
  • Allergic (drug hypersensitivity) reactions - such as a rash, red skin, swelling of your tongue and/or throat, shortness of breath, changes in blood pressure or heart rate, sometimes resulting in a serious decrease of blood pressure. Severe allergic or allergic-like reactions can be life threatening.
    Allergic reactions were reported more commonly in healthy, conscious volunteers
  • Return of muscle relaxation after the operation

Frequency not known

  • Severe slowing of the heart and slowing of the heart up to cardiac arrest may occur when Bridion is administered

Reporting of side effects

If you get any side effects, talk to your anaesthetist or other doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Bridion

Storage will be handled by healthcare professionals.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the label after ‘EXP’. The expiry date refers to the last day of that month.

Store below 30°C. Do not freeze. Keep the vial in the outer carton in order to protect from light.

After first opening and dilution, store at 2 to 8°C and use within 24 hours.

6. Contents of the pack and other information

What Bridion contains

  • The active substance is sugammadex.
    1 mL solution for injection contains sugammadex sodium equivalent to 100 mg sugammadex.
    Each vial of 2 mL contains sugammadex sodium equivalent to 200 mg sugammadex.
    Each vial of 5 mL contains sugammadex sodium equivalent to 500 mg sugammadex.
  • The other ingredients are water for injections, hydrochloric acid 3.7% and/or sodium hydroxide.

What Bridion looks like and contents of the pack

Bridion is a clear and colourless to slightly yellow solution for injection.

It comes in two different pack sizes, containing either 10 vials with 2 mL or 10 vials with 5 mL solution for injection.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

Manufacturer

  • N.V. Organon
    Kloosterstraat 6
    5349 AB Oss
    The Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom
Merck Sharp & Dohme Limited
Tel:+ 44 (0) 1992 467272
Email: medicalinformationuk@merck.com

This leaflet was last revised in July 2018

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.

© Merck Sharp & Dohme Limited 2018. All rights reserved.

PIL.BRI.18.UK.6446.T-030